To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: FDA Approves Triamcinolone Acetone Formulation for Ocular Use URL: http://www.pslgroup.com/dg/223ADE.htm Doctor's Guide June 17, 2008
IRVINE, Calif. -- June 17, 2008 -- The US Food and Drug Administration (FDA) has approved triamcinolone acetonide injectable suspension (Trivaris) 80 mg/mL, a synthetic glucocorticoid corticosteroid with anti-inflammatory action. Delivered via intravitreal injection, the ophthalmic indications for triamcinolone acetonide include sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. These are inflammatory conditions that can result in vision loss. Prolonged use of corticosteroids may produce posterior subcapsular cataracts and glaucoma with possible damage to the optic nerves, and may enhance the establishment of secondary ocular infections. SOURCE: Allergen Inc. --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.